7 › 7.5 › 7.5.11
7.5.11 Temporary mechanical circulatory support
Pages 51–52 · open in PDF
Recommendations in this section
- Class ILevel COxygen is recommended in patients with SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia.
- Class ILevel CIntubation is recommended in patients with DHF and persistent and progressive respiratory failure despite oxygen administration or non-invasive ventilation to correct hypoxaemia.
- Class IIaLevel B2Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO2 <90%) and started as soon as possible in order to decrease respiratory distress and reduce the risk of endotracheal intubation.
- Class ILevel AIntravenous loop diuretics are recommended for all patients with DHF admitted with fluid overload to improve symptoms.
- Class IIaLevel B1The addition of short-term intravenous acetazolamide or oral hydrochlorothiazide should be considered in patients with fluid overload previously treated with loop diuretics, to reduce congestion.
- Class IIbLevel B1Urinary Na⁺-guided diuretic therapy may be considered during the first days of treatment of patients with DHF to improve natriuresis and diuresis.
- Class ILevel B1In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion symptoms and reduce the risk of HFH.
- Class IIbLevel CIntravenous vasodilators may be considered as initial therapy in patients with DHF and systolic blood pressure >110 mmHg to improve symptoms and reduce congestion.
- Class IIbLevel CInotropic agents may be considered in patients with systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion.
- Class IIbLevel CVasopressors, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ perfusion.
- Class IIILevel CRoutine use of opiates is not recommended in patients with DHF unless severe/intractable pain or anxiety, due to risk of harm.
- Class ILevel CA multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type) based on patient and HF characteristics.
- Class IIaLevel B1Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with left ventricular systolic dysfunction and no risk of hypoxic brain injury in order to reduce the risk of death.
- Class IIILevel B1Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of harm.
- Class IIILevel B1IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect.
- Class IIaLevel CTemporary MCS should be considered in patients with mechanical complications related to MI as a bridge to definitive treatment.
- Class IIaLevel CTemporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB, BTC, or BTT.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 51 · PDF
suggests that temporary MCS are beneficial in highly selected patients with ST-elevation MI complicated by CS who do not have hypoxic brain injury, although rates of severe complications remain high.546
SGLT2-I In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion
symptoms and reduce the risk of HFH.492,522,525,541
7.5.11.1. Microaxial flow pumps
Vasodilators initial therapy in patients with DHF and systolic blood pressure >110 mmHg to improve
symptoms and reduce congestion.534 Inotropic agents Inotropic agents may be considered in patients with systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion. Vasopressors Vasopressors, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ Opiates Routine use of opiates is not recommended in patients with DHF unless severe/intractable pain or anxiety, due to risk of harm.542
DHF, decompensated heart failure; HFH, heart failure hospitalization; NIV, non-invasive ventilation; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of oxygen; QoL, quality of life; SGLT2-I, sodium–glucose co-transporter 2 inhibitor; SpO2, oxygen saturation. a Class of recommendation. b Level of evidence. c Criteria for endotracheal intubation in DHF: cardiac or respiratory arrest, progressive worsening of altered mental status, progressive worsening of respiratory failure with hypoxaemia (PaO2 <60 mmHg, PaCO2 >50 mmHg and pH <7.35) despite NIV or intolerance to NIV, persistent haemodynamic instability, need for airway protection.477 d This recommendation is considered by the Task Force to have level of evidence A due to clear clinical benefit. Treatment of DHF with loop diuretics has been widely accepted as effective and therefore no adequately powered randomized clinical trial has ever been conducted or is likely to be conducted for ethical reasons.
7.5.11. Temporary mechanical circulatory support Temporary MCS should be considered as an option for stabilizing haemodynamics and enhancing end-organ perfusion in highly selected patients.434,474,543,544 Different percutaneous devices operate through distinct mechanisms, delivering diverse haemodynamic support levels, each associated with specific potential benefits but also possible complications. In addition to single use, multiple combinations are feasible, addressing specific needs for LV unloading or combined left and right ventricular support. Decisions on the modality and type of temporary MCS should be guided by a multidisciplinary Shock Team including a cardiologist specialized in HF, a cardiothoracic surgeon, an interventional cardiologist, and an intensive care specialist, working at an experienced advanced HF centre (i.e. highvolume for temporary MCS).488,545 A recent meta-analysis
7.5.11.2. Venoarterial extracorporeal life support Extracorporeal life support (ECLS) can deliver support of up to 6 l/min and provide full respiratory and circulatory support. In the ECLS-SHOCK trial involving patients with severe infarct-related CS, early routine ECLS use showed no significant difference in 30-day all-cause death (relative risk 0.98; 95% CI 0.80–1.19).552 These data are in line with an individual patient data meta-analysis of ECLS RCTs in patients with infarct-related CS in which no mortality benefit was observed but more complications with ECLS were seen.553 Importantly, ECLS may harm the heart itself owing to the afterload increase by generation of retrograde blood flow. Active unloading with microaxial flow pumps or intra-aortic balloon pump (IABP) aims to mitigate these adverse effects. A recent RCT comparing routine LV unloading by a transseptal left atrial cannula vs ECLS alone showed no effect on death.554 RCTs investigating the efficacy of ECLS in non-ischaemic CS have yet to be performed.
7.5.11.3. Intra-aortic balloon pump Routine use of IABP is not recommended in unselected patients with CS. In the IABP shock trial, 40 patients with post-MI CS were randomised to IABP treatment or standard of care. Treatment with IABP did not significantly augment cardiac output or any other haemodynamic variable as compared to control.555 In a large-scale RCT in infarct-related CS, routine use of IABP did not show a survival benefit compared with medical therapy at 30-day and longer follow-up.556–558 Also, in advanced HF CS, IABP had no survival benefit as compared to standard of care.559,560 The decision to use an IABP should therefore be highly individualized, based on patient-specific factors and the availability of alternative therapies.559,561–563
Intravenous vasodilators may be considered as
Microaxial percutaneous flow pumps provide support of up to 4 l/min. Newer devices with 5.5 l/min requiring surgical insertion offer complete LV support. Until recently, the percutaneous device had been investigated in a few RCTs on infarct-related CS and in large-scale propensity-matched studies encompassing more than 100 000 patients and consistently showed no survival benefit with higher complication rates such as major bleeding and limb ischaemia.547,548 In the DanGer Shock trial, including 360 highly selected patients with ST-elevation MI and CS, treatment with microaxial flow pump vs standard of care was associated with lower 180-day death (HR 0.74; 95% CI 0.55–0.99; P = .04), which persisted up to 10-year follow-up.549,550 This trial also showed an increased incidence of bleeding and limb ischaemia compared with controls. Despite the mortality benefit observed in this trial, multiple open questions remain.548,551 Utilization of microaxial flow pumps should be considered in highly selected patients with CS caused by ST-elevation MI, who do not have risk of hypoxic brain injury. Routine use of microaxial flow pumps in CS is not recommended. RCTs on the efficacy of microaxial flow pumps in non-infarct-related CS have yet to be conducted.546
Page 52 · PDF
Recommendation Table 10 — Recommendations for the use of temporary mechanical circulatory support in patients with cardiogenic shock (see Evidence Tables 68 and 69)
A multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type)
based on patient and HF characteristics.564,565 Cardiogenic shock caused by acute MI Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with left ventricular systolic dysfunction and no
risk of hypoxic brain injuryc in order to reduce the risk of death.546,549,550 Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of
All the following criteria must be present despite FMT, AMT, and GDIT: 1. Severe and persistent symptoms of HF (NYHA class III or IV). III
2. Severe cardiac dysfunction defined by at least one of the
• LVEF ≤30% • Isolated RV failure (e.g. ARVC)
IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect.557,560
• Non-operable severe valve abnormalities • Non-operable severe congenital abnormalities • Persistently high (or increasing) BNP or NT-proBNP values and
MI-related mechanical complications Temporary MCSd should be considered in patients with mechanical complications related
Criteria for definition of advanced heart failure
severe LV diastolic dysfunction or structural abnormalities (i.e. IIa
HFpEF,a hypertrophic or restrictive cardiomyopathies).
3. Episodes of pulmonary or systemic congestion requiring high-dose
Advanced HF cardiogenic shock
i.v. diuretics (or diuretic combinations) or malignant arrhythmias causing ≥2 unplanned visits or hospitalizations in the last 12 months,
Temporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB,
BTC, or BTT. BTB, bridge to bridge; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; HF, heart failure; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; MI, myocardial infarction; VA-ECLS, venoarterial extracorporeal life support. a Class of recommendation. b Level of evidence. c No risk of hypoxic brain injury was defined as: (i) no out-of-hospital cardiac arrest with persistent Glasgow coma scale <8 after return of spontaneous circulation549; and (ii) no resuscitation or resuscitation lasting <10 min.546 d The choice of passive IABP or active percutaneous MCS should be based on the severity of cardiogenic shock as assessed by the Shock Team. e In case of large ventricular septal defect, temporary MCS should be used with caution due to the potential increase of left-to-right interventricular shunt (VA-ECLS) or shunt inversion (microaxial flow pump). In case of ventricular free-wall rupture, temporary MCS should be avoided; however, VA-ECLS can be considered to allow emergent cardiac surgery in patients presenting with profound cardiogenic shock and/or cardiac arrest if no sign of irreversible brain injury is present.
7.5.12. Thromboembolism prophylaxis Although patients with DHF are recognized as being at increased thromboembolic risk, no RCT has compared anticoagulation vs placebo in a DHF population, thus no definitive recommendation can be made.566–570 However, in case of immobilization or other risk factors, thromboembolic prophylaxis is generally indicated.
to MI as a bridge to definitive treatment.
or ≥1 episode of low output requiring inotropes or vasoactive drugs. 4. Severe impairment of exercise capacity with inability to exercise, or low 6-min walk test distance (<300 m), or pVO2 <12–14 mL/kg/ min,b or <50% predicted value, estimated to be of cardiac origin. AMT, additional medical therapy; ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, B-type natriuretic peptide; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; i.v., intravenous; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; pVO2, peak oxygen consumption; RV, right ventricular. a See Table 10. b The cut-off 12 mL/kg/min refers to patients on beta-blocker.
A severely reduced LVEF is common but not required for a diagnosis of advanced HF, as it may develop in patients with HFpEF or other structural abnormalities. Early risk stratification and timely referral to an advanced HF centre are crucial to improve outcomes (Figure 16).574,575 Systematic assessment for advanced HF using the ‘Rule of three’ or ‘I NEED HELP’ criteria is essential for timely referral to an advanced HF centre576–578 (Figure 16 and Table 15). Cardiopulmonary exercise testing and right heart catheterization (RHC) are key tools for risk stratification and eligibility assessment.579–582 Women and sociocultural minority groups are less likely to receive MCS and heart transplantation for reasons not explained by medical factors or social determinants of health and deserve extra attention for timely referral and patient communication.583–585
Many patients with HF progress into a phase of advanced HF (stage D), characterized by persistent severe symptoms and objective measures of cardiogenic impairment despite optimal therapy. In the Framingham population, 5.1%–7.7% of patients with HF had advanced HF.571 Prognosis in medically treated patients with advanced HF remains poor with 1-year mortality >40%.572,573 Criteria for definition are reported in Table 14.572
8.1. Epidemiology, definition, prognosis, and referral